<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85508">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01684150</url>
  </required_header>
  <id_info>
    <org_study_id>EPZ-5676-12-001</org_study_id>
    <nct_id>NCT01684150</nct_id>
  </id_info>
  <brief_title>A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation &amp; Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK &amp; PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety
      of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary
      assessment of the anti-leukemia activity of EPZ-5676 in patients with acute leukemias
      bearing rearrangements of the MLL gene.

      Currently this study is in the MLL-r restricted/expansion phase and is only enrolling
      patients with rearrangements involving the MLL gene, including 11q23 or partial tandem
      duplications (PTD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A subset of patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia
      (ALL) harbor rearrangements of the MLL gene, which are detected either by cytogenetic or
      fluorescent in situ hybridization evaluation at the time of diagnosis. A protein called
      DOT1L plays an important role in the malignant process in these leukemias. EPZ-5676 is a
      molecule that blocks the activity of DOT1L, and is therefore being evaluated in the
      treatment of patients with MLL-rearranged leukemias.

      This is a first-in-human study of EPZ-5676. The primary purpose of this study is to
      determine what dose of EPZ-5676, when administered as a 21-day continuous intravenous
      infusion, can be given safely to patients with hematologic malignancies. The study will have
      two phases. The first phase will assess escalating doses of EPZ-5676 in order to determine
      the maximally tolerated dose (MTD) or recommended phase 2 dose (RP2D) of EPZ-5676.  Once the
      MTD or RP2D is established, a second phase of the study will further evaluate the safety of
      EPZ-5676 given as a 28-day continuous IV infusion and assess the anti-leukemia activity of
      EPZ-5676 in MLL-rearranged leukemia.

      Currently this study is in the MLL-r restricted/expansion phase and patients will receive
      EPZ-5676 as a continuous intravenous infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of EPZ-5676 as determined by incidence of protocol-specified dose-limiting adverse events.</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The MTD is defined as the dose level below in which &gt;1 patient out of 3 or &gt;2 patients out of 6 experience dose-limiting adverse events (as defined by the protocol).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of EPZ-5676</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>analysis of Cmax, AUC and steady state concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events in patients treated with EPZ-5676</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of adverse events, vital signs, physical examination, 12-lead ECG, and laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-leukemic activity of EPZ-5676 in patients with acute leukemia harboring a MLL-rearrangement</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation of response by standard criteria for AML or ALL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of EPZ-5676 on histone H3K79 methylation in peripheral blood mononuclear cells (PBMC).</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of EPZ-5676 on histone H3K79 methylation in leukemia cells</measure>
    <time_frame>up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myeloproliferative Disorders</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>EPZ-5676 Dose-escalation and extension cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPZ-5676</intervention_name>
    <description>MLL-r restricted/expansion phase with option to dose escalate, 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.</description>
    <arm_group_label>EPZ-5676 Dose-escalation and extension cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients aged ≥ 18 years.

          2. Patients with relapsed /refractory AML, ALL, or MLL with rearrangement of the MLL
             gene, including 11q23 or PTD, are eligible for the expanded cohort:

               -  At least one prior therapy;

               -  Refractory disease on most recent therapy, or disease recurrence following
                  remission on most recent therapy;

               -  Received and failed all known effective therapies for their disease;

               -  Not a candidate for allogeneic stem cell transplantation

               -  &gt; 10% blasts or biopsy-documented leukemia cutis or myeloid sarcoma.

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          4. Patients must have the following clinical laboratory values:

               -  Serum creatinine ≤2 mg/dL or creatinine clearance &gt; 60 mL/minute;

               -  Total bilirubin ≤2.0 times the ULN for the institution, unless considered due to
                  Gilbert's syndrome;

               -  ALT or AST ≤ twice the upper limit of normal (ULN), unless considered due to
                  organ leukemic involvement;

               -  Absolute neutrophil count ≥1,000/µL (unless due to documented leukemic
                  involvement of the bone marrow at the time of study entry)

               -  Platelets ≥100,000/µL (unless due to documented leukemic involvement of the bone
                  marrow at the time of study entry).

               -  PT or aPTT &lt; 1.5 times the ULN

          5. Able and willing to give written informed consent.

          6. Life expectancy of at least 3 months

        Exclusion Criteria:

          1. Uncontrolled intercurrent illness or psychiatric illness/social situations that would
             limit compliance with study requirements.

          2. Active heart disease

          3. Receiving any other standard treatment for their hematologic malignancy.

          4. Receiving strong CYP3A4 inhibitors/ inducers.

          5. Known history of cerebrovascular accident in the past 6 months.

          6. Known bleeding diathesis.

          7. Known, active (symptomatic) involvement of the central nervous system by leukemia.

          8. On immunosuppressive therapy.

          9. Known active infection.

         10. Pregnant or nursing females.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin S. Tallman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Berdeja, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Rizzieri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillermo Garcia-Manero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica Altman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raoul Tibes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Scottsdale-Phoenix</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mojca Jongen-Lavrencic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hartmut Döhner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eric Hedrick, MD</last_name>
    <phone>855-500-1011</phone>
    <email>clinicaltrials@epizyme.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale-Phoenix</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raoul Tibes, MD</last_name>
      <phone>480-301-8335</phone>
      <email>Tibes.Raoul@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Raoul Tibes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Altman, MD</last_name>
      <phone>312-695-0990</phone>
      <email>j-altman@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jessica Altman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin S Tallman, MD</last_name>
      <phone>212-639-3842</phone>
      <email>TallmanM@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Martin S Tallman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A Rizzieri, MD</last_name>
      <phone>919-668-1014</phone>
      <email>rizzi003@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>David A Rizzieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus Berdeja, MD</last_name>
      <phone>615-329-7274</phone>
      <email>jberdeja@tnonc.com</email>
    </contact>
    <investigator>
      <last_name>Jesus Berdeja, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT MD Anderson Cancer</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Garcia-Manero, MD</last_name>
      <phone>713-745-3428</phone>
    </contact>
    <investigator>
      <last_name>Guillermo Garcia-Manero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartmut Döhner, MD</last_name>
      <email>hartmut.doehner@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Hartmut Döhner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojca Jongen-Lavrencic, MD</last_name>
      <email>m.lavrencic@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Mojca Jongen-Lavrencic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 4, 2014</lastchanged_date>
  <firstreceived_date>September 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Advanced hematologic malignancies</keyword>
  <keyword>Epizyme</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Mixed Lineage Leukemia (MLL)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
